Coronary Artery Bypass Grafts Articles & Analysis
23 news found
Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21. The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary ...
About the EXACT Study The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) clinical trial is a Phase 1/2 multicenter, open-label, single-arm trial. ...
About the EXACT Study The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) clinical trial is a Phase 1/2 multicenter, open-label, single-arm trial. ...
Xeltis currently has three restorative devices in clinical trial phase, including aXess – a restorative access graft for dialysis; XABG – which is a coronary artery bypass graft; and its pulmonary heart valve, which was the first ever synthetic valve to enter a pivotal trial (Xplore2/Pivotal) in July ...
The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ clinical trial program for its XABG device, the first-ever restorative Coronary Artery Bypass Graft (CABG). XABG is a restorative, synthetic blood vessel device that turns into a living blood vessel when ...
Emmert (German Heart Center and Charite Universitatsmedizin, Berlin Germany) Friday, December 3 at the 7th Annual International Coronary Congress in New York City. The GOAL Study is an independent investigator observational clinical study to assess the role of vascular graft /storage solutions on myocardial protection during coronary ...
These patents protect Marizyme’s flagship commercial product DuraGraft®, a first-in-class CE marked intra-operative graft storage solution. DuraGraft® protects vascular grafts against ischemic injury during bypass surgeries by reducing the incidence of complications associated with vein graft failure, leading to ...
” Xeltis’ devices are vascular grafts and heart valves designed to turn into living valves and vessels by harnessing the body’s natural healing process and by facilitating tissue formation once implanted. ...
The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery ...
Taylor, Chief of the Division of Cardiac Surgery and Director of Coronary Revascularization and site Principal Investigator at the University of Maryland Medical Center. ...
An estimated one million people suffer from refractory angina in the United States. About Coronary Artery Bypass Graft Surgery (CABG) CABG is a procedure used to treat coronary artery disease — the narrowing or blockage of the blood vessels that supply oxygen and nutrients to the heart ...
In addition to its restorative pulmonary valve, Xeltis has developed the first-ever restorative synthetic coronary artery bypass graft (CABG) to have shown successful long-term results in long preclinical trials and the first-ever restorative synthetic vascular access graft for patients that need ...
"We are excited to partner with Marizyme and bring this pivotal product DuraGraft to the Chilean health care market," said Konrad Ziller, Managing Director for Abdera. "DuraGraft will enhance coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat ...
(OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors. ...
(OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. ...
Abel Alexander, Regency Lifesciences CEO, said, "This approval and licensure represents a significant step toward providing this novel treatment to the estimated 60,000 Coronary Artery Bypass Graft Surgeries per year." About CABG and DuraGraft When patients with heart disease undergo CABG surgery, free vein or ...
Mehran Khorsandi and medical devices engineer Henry Bourang, ABS is positioned to solve one of the most technically challenging problems – the treatment of coronary bifurcation lesions - that has eluded the medical device world since coronary stents were first implanted in humans in 1986. Coronary bifurcation lesions are prevalent in about ...
The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary intervention. XC001 is an investigational novel gene therapy designed to activate naturally occurring biological pathways to improve blood flow to areas of the heart not ...
The disease that Bilix has targeted is ischemic reperfusion injury caused by organ transplantation, myocardial infarction, coronary artery bypass grafting, and stroke. In the case of myocardial infarction, it occurs after a patient undergoes a stent procedure. ...
Following the completion of two Phase II surgery trials in ECS and coronary artery bypass graft surgery, and a final European Medicines Agency advice letter, a European pivotal trial with Elafin in ECS is in preparation. ...